LXRX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Lexicon Pharmaceuticals completes enrollment in the pivotal Phase 3 SONATA-HCM trial of sotagliflozinJul 27, 2026
- Lexicon Pharmaceuticals and Novo Nordisk initiated a Phase 1 study for oral obesity drug candidate LX9851Mar 23, 2026
- Lexicon will present data on how kidney function affects long-term efficacy and safety of sotagliflozin in type 1 diabetesMar 11, 2026
- Lexicon Pharmaceuticals completed successful End-of-Phase 2 FDA meeting for pilavapadinJan 21, 2026
- Lexicon Pharmaceuticals announces update on submission of additional data to U.S. FDA supporting benefit-risk profile of Zynquista® in Type 1 diabetesSep 23, 2025